Conclusion
The BAT can be seen as a surrogate of immediate allergic reactions in
vitro and thus support the diagnosis of allergic diseases and its
monitoring during immunomodulatory treatments (Table 4). A robust
laboratory method which can provide consistent and reliable results that
have been clinically validated can be extremely valuable both for
clinical practice and for clinical trials into existing and novel
treatments for allergic disease. Standardisation and continuous quality
assurance as well as training of health care professionals on the
interpretation of BAT results are important for further implementation
of BAT in clinical practice and allergy research.